Table 4. Relative incidence of medically attended adverse events of interest in the pre-exposure and risk periods following COVID-19 vaccination for both doses by vaccine brand, England, 1 October 2020–12 September 2021 (n = 1,304,447 events including control period).

Model	Comirnaty		Vaxzevria		Spikevax
Model	RI	95% CI	RI	95% CI	RI	95% CI
Model 1
D1: −7 to −1	0.96***	0.94–0.98	0.96***	0.94–0.98	1.02	0.96–1.09
D1: 0 to 7	0.92***	0.90–0.94	0.96***	0.94–0.97	1.05	1.00–1.12
D2: −7 to −1	0.91***	0.89–0.93	0.96***	0.94–0.98	1.00	0.94–1.07
D2: 0 to 7	0.94***	0.92–0.96	0.95***	0.94–0.97	1.07*	1.01–1.14
Model 2
D1: −7 to −1	0.96***	0.94–0.98	0.97***	0.95–0.98	1.16	0.95–1.41
D1: 0 to 7	0.93***	0.91–0.94	0.97***	0.95–0.98	1.20*	1.00–1.44
D2: −7 to −1	0.92***	0.90–0.94	0.96***	0.95–0.98	1.07	0.95–1.35
D2: 0 to 7	0.96***	0.94–0.98	0.97***	0.95–0.98	1.13	0.91–1.39
D1: −7 to −1 x age	0.9978***	0.9970–0.9987	0.9988*	0.9978–0.9999	1.0094	0.9990–1.0199
D1: 0 to 7 x age	0.9973***	0.9965–0.9982	0.9982***	0.9973–0.9992	1.0035	0.9944–1.0128
D2: −7 to −1 x age	0.9981***	0.9972–0.9991	0.9993	0.9982–1.0004	1.0062	0.9932–1.0193
D2: 0 to 7 x age	0.9965***	0.9956–0.9973	0.9979***	0.9968–0.9989	0.9988	0.9874–1.0103

COVID-19: coronavirus disease; D1: vaccine dose 1; D2: vaccine dose 2.

Days –7 to –1 refers to the pre-exposure period and days 0 to 7 refers to the risk period.

Significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001.

Age centred at 50 years in Model 2.